Epirubicin (E) followed by cyclophosphamide, methotrexate, 5-fluorouracil (CMF) versus paclitaxel (T) followed by epirubicin and vinorelbine (EV) in patients (pts) with high-risk operable breast cancer

被引：0
|
作者：
Boccardo, F. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Rubagotti, A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Guglielmini, P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Sismondi, P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Farris, A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Amadori, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Agostara, B. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Gambi, A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Catalano, G. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Faedi, M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
机构：
[1] Univ Genoa, Natl Inst Canc Res, Genoa, Italy
[2] Univ Mauriziano, Molinette Mauriziano Hosp, Turin, Italy
[3] Univ Sassari, I-07100 Sassari, Italy
[4] Tumor Inst Meldola, Forli, Italy
[5] M Ascoli Hosp, Palermo, Italy
[6] Infermi Hosp, Faenza, Italy
[7] Gen Hosp Pesaro, Pesaro, Italy
[8] Osped Gen Provinciale M Bufalini, Cesena, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11521
引用
收藏
页数：2
相关论文
共 50 条
  • [41] European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF).
    Gianni, L
    Baselga, J
    Eiermann, W
    Porta, VG
    Semiglazov, V
    Lluch, A
    Zambetti, M
    Valagussa, P
    Bonadonna, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 7S - 7S
  • [42] Epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) versus fluorouracil, epirubicin and cyclophosphamide (FEC) followed by T, all given every 3 weeks or 2 weeks, in node-positive early breast cancer (BC) patients (pts). Final results of the gruppo Italiano mammella (GIM)-2 randomized phase III study
    Cognetti, F.
    Bruzzi, P.
    De Placido, S.
    De laurentiis, M.
    Boni, C.
    Aitini, E.
    Durando, A.
    Turletti, A.
    Valle, E.
    Garrone, O.
    Puglisi, F.
    Montemurro, F.
    Barni, S.
    Di Blasio, B.
    Gamucci, T.
    Colantuoni, G.
    Olmeo, N.
    Tondini, C.
    Parisi, A. M.
    Bighin, C.
    Pastorino, S.
    Lambertini, M.
    Del Mastro, L.
    CANCER RESEARCH, 2013, 73
  • [43] 5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial
    Del Mastro, Lucia
    Levaggi, Alessia
    Michelotti, Andrea
    Cavazzini, Giovanna
    Adami, Francesca
    Scotto, Tiziana
    Piras, Margherita
    Danese, Saverio
    Garrone, Ornella
    Durando, Antonio
    Accortanzo, Valeria
    Bighin, Claudia
    Miglietta, Loredana
    Pastorino, Simona
    Pronzato, Paolo
    Castiglione, Federico
    Landucci, Elisabetta
    Conte, PierFranco
    Bruzzi, Paolo
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (01) : 117 - 126
  • [44] 5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial
    Lucia Del Mastro
    Alessia Levaggi
    Andrea Michelotti
    Giovanna Cavazzini
    Francesca Adami
    Tiziana Scotto
    Margherita Piras
    Saverio Danese
    Ornella Garrone
    Antonio Durando
    Valeria Accortanzo
    Claudia Bighin
    Loredana Miglietta
    Simona Pastorino
    Paolo Pronzato
    Federico Castiglione
    Elisabetta Landucci
    PierFranco Conte
    Paolo Bruzzi
    Breast Cancer Research and Treatment, 2016, 155 : 117 - 126
  • [45] The Efficacy and Safety of Preoperative Chemotherapy With Triweekly Abraxane and Cyclophosphamide Followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Therapy for Resectable Breast Cancer: A Multicenter Clinical Trial
    Shigematsu, Hideo
    Kadoya, Takayuki
    Masumoto, Norio
    Sasada, Tatsunari
    Emi, Akiko
    Ohara, Masahiro
    Kajitani, Keiko
    Okada, Morihito
    CLINICAL BREAST CANCER, 2015, 15 (02) : 110 - 116
  • [46] Risk of venous thromboembolism in patients receiving adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide for early breast cancer
    Hoy, Julia
    Neeman, Teresa
    Stuart-Harris, Robin
    Davis, Alison
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2009, 5 (02) : 129 - 136
  • [47] Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group
    Fountzilas, G
    Skarlos, D
    Dafni, U
    Gogas, H
    Briasoulis, E
    Pectasides, D
    Papadimitriou, C
    Markopoulos, C
    Polychronis, A
    Kalofonos, HP
    Siafaka, V
    Kosmidis, P
    Timotheadou, E
    Tsavdaridis, D
    Bafaloukos, D
    Papakostas, P
    Razis, E
    Makrantonakis, P
    Aravantinos, G
    Christodoulou, C
    Dimopoulos, AM
    ANNALS OF ONCOLOGY, 2005, 16 (11) : 1762 - 1771
  • [48] Sequential dose-dense 5-fluorouracil, epirubicin and cyclophosphamide followed by docetaxel in patients with early breast cancer with four or more positive lymph nodes
    Murialdo, Roberto
    Gallo, Maurizio
    Boy, Davide
    Zoppoli, Gabriele
    Tixi, Lucia
    Gonella, Roberta
    Ballestrero, Alberto
    Patrone, Franco
    TUMORI JOURNAL, 2014, 100 (02): : 128 - 135
  • [49] CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
    Esteva, Francisco J.
    Wang, Jing
    Lin, Feng
    Mejia, Jaime A.
    Yan, Kai
    Altundag, Kadri
    Valero, Vicente
    Buzdar, Aman U.
    Hortobagyi, Gabriel N.
    Symmans, W. Fraser
    Pusztai, Lajos
    BREAST CANCER RESEARCH, 2007, 9 (06)
  • [50] CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
    Francisco J Esteva
    Jing Wang
    Feng Lin
    Jaime A Mejia
    Kai Yan
    Kadri Altundag
    Vicente Valero
    Aman U Buzdar
    Gabriel N Hortobagyi
    W Fraser Symmans
    Lajos Pusztai
    Breast Cancer Research, 9
12345